...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta oncologica. >Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
【24h】

Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis

机译：高加索肾细胞癌中孙尼尼患者的孙初差异评价：荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: An increasing number of studies have reported ethnic differences in sunitinib outcome in metastatic renal cell carcinoma (mRCC) patients. However, a comprehensive analysis is still lacking. Therefore, we systematically collected available published data and performed a meta-analysis to compare sunitinib efficacy and toxicity in Asian and Caucasian mRCC patients.Methods: Data were extracted from published results from clinical trials, expanded access program and real-world clinical practice. Progression-free survival (or time to tumor progression), overall survival, objective response rate and adverse events were used as endpoints to evaluate the differences of sunitinib outcome between the two ethnicities. For adverse events, we focused the following clinically relevant side effects: diarrhea, fatigue, mucositis/stomatitis, hand-foot syndrome, hypertension, leukopenia, neutropenia and thrombocytopenia.Results: A total of 33 publications including 9977 patients were available for meta-analysis. The efficacy of sunitinib in Asian patients was similar to that in Caucasian patients. However, Asian patients showed a higher incidence of all grades toxicity of hand-foot syndrome, >grade 2 fatigue, >grade 2 hand-foot syndrome and >grade 2 thrombocytopenia.Conclusion: Ethnic differences in adverse events of sunitinib in mRCC patients existed and dose adjustment in Asian patients may be considered.
机译：背景：越来越多的研究已经报道了孙氨基蛋白癌（MRCC）患者的孙氨基蛋白结果的族裔差异。但是，仍然缺乏综合分析。因此，我们系统地收集了已发布的数据，并进行了荟萃分析，以比较亚洲和高加索MRCC患者的孙氨inib疗效和毒性。方法：数据从临床试验中发表的结果提取，扩大访问计划和现实世界临床实践。无进展的存活（或肿瘤进展时间），总体存活，客观反应率和不良事件被用作终点，以评估两种种族之间的逊型尼的结果的差异。对于不良事件，我们专注于以下临床相关的副作用：腹泻，疲劳，粘膜炎/口腔炎，手足综合征，高血压，白细胞减少症，中性粒细胞和血小板减少症。结果：33例出版物，包括9977名患者，可用于荟萃分析。桑顿在亚洲患者中的疗效与高加索患者的疗效相似。然而，亚洲患者出现了患有手足综合征的所有患者毒性的发病率较高，> 2级疲劳，> 2级手足综合征和> 2级血小板减少症。结论：MRCC患者孙尼替尼的不良事件族差异存在可以考虑亚洲患者的剂量调整。

著录项

  • 来源
    《Acta oncologica.》 |2017年第6期|共8页
  • 作者

    Liu Xiaoyan; Fiocco Marta; Swen Jesse J.; Guchelaar Henk-Jan;

  • 作者单位

    Leiden Univ Dept Clin Pharm &

    Toxicol Med Ctr Albinusdreef 2 NL-2333 ZA Leiden Netherlands;

    Leiden Univ Dept Med Stat &

    Bioinformat Med Ctr Leiden Netherlands;

    Leiden Univ Dept Clin Pharm &

    Toxicol Med Ctr Albinusdreef 2 NL-2333 ZA Leiden Netherlands;

    Leiden Univ Dept Clin Pharm &

    Toxicol Med Ctr Albinusdreef 2 NL-2333 ZA Leiden Netherlands;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号